Delving into the Latest Updates on Guselkumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Guselkumab (Genetical Recombination), Guselkumab (genetical recombination) (JAN), Guselkumab (USAN)

+ [8]

Target

IL-23p19

Action

inhibitors

Mechanism

IL-23p19 inhibitors(Interleukin-23 subunit p19 inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesCongenital Disorders+ [5]

Active Indication

Crohn's disease, active moderateCrohn's disease, active severeUlcerative colitis, active moderate+ [23]

Inactive Indication

Adenomatous Polyposis ColiCeliac DiseaseGeneralized Pustular Psoriasis+ [7]

Originator Organization

Janssen Global Services LLC

Active Organization

Janssen-Cilag International NVJanssen Scientific Affairs LLCJanssen Research & Development LLC

+ [11]

Inactive Organization-

License Organization

Janssen Pharmaceuticals, Inc.

Celsius Therapeutics, Inc.

MorphoSys AG

+ [3]

Drug Highest PhaseApproved

First Approval Date

United States (13 Jul 2017),

Plaque psoriasis

RegulationOrphan Drug (Japan), Overseas New Drugs Urgently Needed in Clinical Settings (China), Breakthrough Therapy (China), Priority Review (China)

Login to view timeline

Structure/Sequence

Sequence Code 9493545H

Source: *****

Sequence Code 9493571L

Source: *****

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.
The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Start Date01 Aug 2026

Sponsor / Collaborator

The University of California, San Francisco

NCT07726888

/ Not yet recruitingNot ApplicableIIT

Efficacy and Safety of Guselkumab in Patients With Moderate-to-Severe Ulcerative Colitis:A Real-World Prospective Cohort Study.

In a real-world setting, this study systematically evaluates the clinical efficacy and safety of guselkumab (GUS) in the treatment of ulcerative colitis (UC), encompassing multi-dimensional outcomes including clinical remission, biochemical remission, endoscopic remission, histologic healing, and intestinal ultrasound changes.

Start Date01 Aug 2026

Sponsor / Collaborator

Second Affiliated Hospital of Wenzhou Medical University

[+1]

NCT07616687

/ RecruitingPhase 4IIT

Optimal Care With Guselkumab In Crohn's Disease

Crohn's disease (CD) is a chronic and destructive inflammatory disease of the gastrointestinal tract characterized by phases of relapse and remission. Tumor necrosis factor (TNF) antagonists, anti-integrins and anti-interleukin (IL) 12/23 are the main therapeutic agents to obtain deep remission and prevent disability. Despite the significant advances these biologics represent in treating inflammatory bowel disease (IBD), many patients experience suboptimal responses, including primary non-response or a loss of effectiveness over time, often leading to treatment discontinuation. For all these medications, a dose-response relationship has been demonstrated and an increase in dose or dosing frequency is recommended. Dose escalation is now an essential therapeutic approach necessary in 30 to 50% of CD patients treated with biologics. This strategy, supported by international guidelines, allows for long-term efficacy to be maintained without compromising safety.
Guselkumab (GUS) is a monoclonal antibody targeting the p19 subunit of IL-23. In a recent phase III trial (GALAXI), GUS demonstrated superiority of both subcutaneous (SC) maintenance doses (200 mg every 4 weeks [q4w] and 100 mg every 8 weeks [q8w]) compared to placebo and ustekinumab. In the GALAXI phase III program, at least 30% of patients did not achieve clinical response after a 12-week intravenous induction, and almost 20% experienced a loss of response by week 44. In these patients, the benefit of an intensified dose of GUS (200 mg q4w) maintenance remains to be determined to guide clinicians in optimizing its use in clinical practice. The investigator aimed to evaluate the one-year effectiveness of GUS in CD in real-world settings and under optimal conditions allowing dose intensification.

Start Date18 Jun 2026

Sponsor / Collaborator-

100 Clinical Results associated with Guselkumab

Login to view more data

100 Translational Medicine associated with Guselkumab

Login to view more data

100 Patents (Medical) associated with Guselkumab

Login to view more data

927

Literatures (Medical) associated with Guselkumab

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies

Article

Author: Zhdanava, Maryia ; Fitzgerald, Timothy ; Feldman, Steven R. ; Boonmak, Porpong ; Schwartzbein, Samuel ; Libchaber, Béatrice ; Pilon, Dominic

OBJECTIVE:

To compare on-label persistence among adults with psoriasis who switched from other advanced therapies to guselkumab versus subcutaneous tumor necrosis factor inhibitors (SC TNFi), subcutaneous interleukin-17 inhibitors (SC IL-17i), or apremilast.

MATERIALS AND METHODS:

This retrospective cohort study used U.S. claims data from the IQVIA PharMetrics® Plus database (2016- 2023). Overlap propensity score weights were used to balance cohorts on baseline characteristics. On-label persistence was defined as the absence of drug discontinuation (event) and any dose change relative to the U.S. label (censoring). Survival analyses were used to assess on-label persistence from the start of the maintenance phase.

RESULTS:

At 12, 18, and 24 months after the start of the maintenance phase, respectively, on-label persistence was 190%, 180%, and 179% more likely on guselkumab versus SC TNFi; 78%, 87%, and 91% more likely on guselkumab versus SC IL-17i; and 187%, 199%, and 193% more likely on guselkumab versus apremilast (all p < 0.001).

CONCLUSIONS:

Patients experiencing suboptimal outcomes with other psoriasis-indicated advanced therapies achieved higher on-label persistence after switching to guselkumab, raising the potential for improved disease control relative to other treatment options.

31 Dec 2026·mAbs

Biparatopic targeting of IL-23 enables dual-epitope engagement and enhanced neutralization potency

Article

Author: Gauntlett, Ross ; Caruana, Richard ; Sinfield, Helen ; Watson, Joe ; Lodge, James ; Cordy, Joanna ; Rattray, Zahra ; Yates, James

Biparatopic antibodies (bpAbs) have two non-overlapping epitopes on a single antigen, offering a distinct therapeutic potential, yet their application to soluble cytokines remains underexplored. Herewithin, we engineered and characterized biparatopic antibodies targeting human interleukin-23 (IL-23) by combining the clinically validated variable regions of ustekinumab and guselkumab into 1 + 1 IgG-like and 2 + 2 Fab-IgG extended biparatopic formats. Constructs were generated using heterodimer promoting C_H3 mutations and redox repair assembly of half‑antibodies, expressed in HEK-2936E cells, and benchmarked against parental monospecific antibodies. An orthogonal analytical workflow, comprising sodium dodecyl sulfate polyacrylamide gel electrophoresis, liquid chromatography-mass spectrometry, analytical size-exclusion chromatography, surface plasmon resonance (SPR), and mass photometry was used to define critical quality attributes and characterize biparatopic target engagement. SPR kinetic analysis demonstrated picomolar affinities across constructs and revealed avidity‑driven enhancements in apparent affinity. A bespoke SPR dual‑engagement bridging assay confirmed simultaneous IL-23A and IL-12B binding, validating obligate biparatopic engagement. Mass photometry independently corroborated in trans immune complex formation and revealed stoichiometry-dependent multimerisation across the bpAb formats explored. Functional neutralization was measured using an IL-23 luciferase reporter assay and supported by a bespoke, two-parameter mechanistic model, which accurately predicted observed EC₅₀ shifts. Biparatopic formats exhibited equivalent potency relative to equimolar antibody mixtures, establishing a generalizable framework for engineering and modeling soluble cytokine‑targeting biparatopic therapeutics.

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER study

Article

Author: Galluzzo, Marco ; Stingeni, Luca ; Pallotta, Sabatino ; Megna, Matteo ; Argenziano, Giuseppe ; Corazza, Monica ; Lasagni, Claudia ; Piaserico, Stefano ; Fargnoli, Maria Concetta ; Costanzo, Antonio ; Bardazzi, Federico ; Offidani, Annamaria ; Richetta, Antonio Giovanni ; Bonifati, Claudio ; Potenza, Concetta ; Atzori, Laura ; Saibene, Federico ; Gramiccia, Talia ; Papini, Manuela ; Giofrè, Claudia ; Di Lernia, Vito Giuseppe ; Dapavo, Paolo ; Bongiorno, Maria Rita ; Prignano, Francesca ; Lembo, Serena ; Savoia, Paola ; Satolli, Francesca ; Burlando, Martina ; Guarneri, Claudio ; Zichichi, Leonardo ; Rongioletti, Franco ; Loconsole, Francesco ; Micali, Giuseppe ; Peris, Ketty ; Donini, Massimo ; Romanelli, Marco ; Stinco, Giuseppe ; Carrera, Carlo Giovanni

OBJECTIVES:

Facial and genital plaques are common manifestations of psoriasis, are challenging to treat, and significantly impact patients' quality of life (QoL).

METHODS:

GULLIVER is a prospective, non-interventional study conducted in 2020-2023 in Italy, aimed at examining the effectiveness, safety and QoL impact of guselkumab through 52 weeks of treatment in patients with facial and/or genital psoriasis. The primary endpoint was the percentage of patients achieving a static Physician Global Assessment (sPGA) score of ≤1 and a minimum 2-grade improvement in sPGA score at Week 52.

RESULTS:

Of 351 enrolled patients, 88.6% remained on guselkumab treatment at Week 52. The proportions of patients achieving the sPGA targets in the facial and genital groups, respectively, were 83.3% and 76.5% at week 12, increasing to 93.8% and 97.9% at Week 52. Mean Dermatology Life Quality Index score improved from 12.0 ± 7.5 at baseline to 1.1 ± 2.0 at Week 52 for patients with facial psoriasis (p-value <0.001) and from 12.0 ± 6.9 to 1.6 ± 3.5 for those with genital psoriasis (p-value <0.001). Guselkumab was well-tolerated and no new safety signals were identified.

CONCLUSIONS:

This Italian real-world study demonstrated the high effectiveness and a good safety profile of guselkumab in treating facial and genital psoriasis.

331

News (Medical) associated with Guselkumab

27 Jul 2026

·www.biospace.com

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera’s industry-leading oral immunology portfolio Jared Gollob, MD, will retire from his role after eight years of leadership at the Company WATERTOWN, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Terence Rooney, MD, as Chief Medical Officer. Dr. Rooney is an accomplished drug development leader with extensive experience advancing immunology therapies across the full development lifecycle, from early clinical stages through commercialization and franchise expansion, helping bring important new medicines to patients around the world. In his role, Dr. Rooney will lead Kymera’s global clinical development strategy and guide the advancement of the Company’s oral immunology portfolio across multiple immuno-inflammatory diseases. He succeeds Jared Gollob, MD, who will retire from his role after eight years with the Company and will remain as an advisor through the end of the year. “We are thrilled to welcome Terence at a time of tremendous momentum and opportunity for our company, with multiple clinical programs advancing and an early innovation engine rooted in bold science and the needs of patients. Terence’s broad development experience, physician-scientist perspective and proven leadership in delivering important immunology medicines to patients at a global scale make him uniquely suited to help us realize the full potential of our pipeline and guide us through this next stage of growth,” said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. “I also want to thank Jared for his extraordinary leadership and partnership. From Kymera’s earliest days, Jared has helped shape not only our development strategy and infrastructure, but also the company we are today, and we are deeply grateful for his significant contributions and unwavering commitment to changing patients’ lives.” ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); “Having spent most of my career in immunology, I have seen firsthand the significant treatment gaps that remain for patients living with these chronic conditions and the importance of advancing science that can truly shift the status quo and evolve care,” said Dr. Rooney. “Kymera stands out for the depth of its science, the execution across its diverse portfolio, and the opportunity to build on this momentum to expand oral treatment options for multiple diseases. I am excited to join the Kymera team at this critical time and advance the Company’s work to improve outcomes for patients around the world.” Prior to joining Kymera, Dr. Rooney served as Senior Vice President, Portfolio and Asset Management Leader, Immunology, at Johnson & Johnson, where he led global compound development teams and portfolio strategy and operations across immunology. Earlier in his career, he held senior leadership roles across immunology R&D at Eli Lilly and Roche, including work at the interface of discovery, translational medicine and clinical development. Across his career, his work has spanned small molecules, peptides, biologics and cell therapies, combination and precision therapy strategies, and therapeutic areas including dermatology, respiratory, rheumatology, gastroenterology and rare diseases. Dr. Rooney has contributed to successful marketing applications for groundbreaking medicines including ICOTYDE ® , IMAAVY ® , OLUMIANT ® , STELARA ® , and TREMFYA ® . Dr. Rooney received his medical degrees from the Royal College of Surgeons in Ireland. He completed his training in internal medicine at the Dublin Academic Teaching Hospitals in Ireland, and rheumatology fellowships both there and at the University of California, San Francisco. He received a doctorate from the National University of Ireland and has authored some 50 peer-reviewed scientific publications. About Kymera Therapeutics Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit or follow us on X or LinkedIn . Investor Contact: Justine Koenigsberg investors@kymeratx.com 857-285-5300 Media Contact: Matthew Henson media@kymeratx.com 857-285-5300

Executive ChangeImmunotherapy

15 Jul 2026

·www.fiercepharma.com

No patent protection for Stelara? No problem for J&J as Tremfya fills the void

After a 7% increase in revenue for the second quarter, which came on the heels of a 10% gain in Q1, Johnson & Johnson has bumped up its annual sales guidance. The company now projects 2026 revenue at the midpoint to land at $101.1 billion, versus a prior midpoint estimate of $100.8 billion. Much of the credit for J&J’s recent performance can be attributed to the resilience of its immunology portfolio, which took a massive hit with the loss of patent protection in the United States for Stelara, its top-selling drug in 2024 at $10.4 billion. Stelara saw its sales decline to $6.7 billion last year. Despite this, J&J has now pieced together five straight quarters of at least 6% revenue growth. In Q2, there was more evidence of the slide of Stelara, with worldwide sales falling (PDF) 55% to $740 million. But compensating for nearly all of that decline was J&J’s new immunology juggernaut Tremfya, which pulled off a 72% sales increase for the period. While Stelara’s worldwide sales dropped by $913 million year over year, those for Tremfya increased by $862 million to $2.05 billion. “The major driver here is our performance in ulcerative colitis and in Crohn’s disease,” Jennifer Taubert, J&J’s innovative medicines chief, said during a conference call, pointing out that Tremfya is attracting more than half of the new patients in both inflammatory bowel disease (IBD) indications as it battles AbbVie’s rival IL-23 med Skyrizi. “We have got an awful lot of growth potential ahead for Tremfya in IBD,” Taubert added. “And as a reminder, back when we had Stelara here, over 75% of Stelara sales were in IBD. There is absolutely no reason why Tremfya can’t do that or even more.” Also in the immunology arena, J&J touted the launch of its newest Il-23 inhibitor, Icotyde, which was approved by the FDA four months ago for plaque psoriasis as a daily pill option in a market flooded with injected biologics. With the launch so new, the company did not specify sales but did say that Icotyde has attracted more than 18,000 prescriptions for 11,000 patients across 6,000 unique prescribers. “That tells us that there’s really good confidence in the product in both the efficacy and safety profile as well as the simplicity of the once-daily pill,” Taubert said. Icotyde and Tremfya give J&J "differentiated oral and biologic approaches across dermatology and potentially IBD," Citi analyst Geoffrey Meacham wrote in a note to clients. "Icotyde momentum and a traditionally stronger second half also contributed to the guidance raise." For the quarter, J&J’s sales came to $25.3 billion, which puts the company on track to top the $100 billion mark for the first time in its 140-year history, CEO Joaquin Duato pointed out on the conference call. He also highlighted the company’s 28 “platforms” that deliver at least $1 billion in sales. Doing much of the remaining heavy lifting for J&J in the second quarter were its oncology drugs, with the portfolio achieving a 17% year-over-year sales increase. Multiple myeloma powerhouse Darzalex was up 19% in the period to $4.2 billion. Meanwhile, J&J’s newer multiple myeloma treatments are also making major gains, with Talvey up 63% to $174 million, Tecvayli up 56% to $260 million and Carvykti up 49% to $657 million. For the quarter, J&J’s oncology drugs amassed sales of $7.4 billion altogether. “We’re on track to become the No. 1 oncology company by 2030 with sales projected to exceed $50 billion,” Duato said.

Drug ApprovalBiosimilar

15 Jul 2026

·firstwordpharma.com

Tremfya surges, Icotyde gains ground as J&J raises bar for 2026

Johnson & Johnson on Wednesday lifted its sales guidance for the year as psoriasis treatments Tremfya and oral newcomer Icotyde are doing heavy work to help offset steep biosimilar erosion for Stelara.Tremfya, an IL-23 inhibitor, beat analyst projections with $2 billion in second-quarter sales, a gain of 72.5% year-over-year, while the company said early uptake of Icotyde, which was approved by the FDA in March, has surpassed expectations. On the flip side, Stelara's second-quarter sales fell 55.2% to $740 million."We're extremely thrilled with the launch of Icotyde for the first 90 days," Chief Financial Officer Joe Wolk told Barron's. "It's exceeding almost any product launch that we've seen in recent memory."Speaking on the earnings call, Jennifer Taubert, J&J's worldwide chairman of Innovative Medicine, said the launch of Icotyde hasn't come at Tremfya's expense either.Over 18,000 prescriptions"We've got this great uptick in Icotyde. This has not slowed down Tremfya in psoriatic disease at all," she said. "In terms of really co-positioning, Icotyde is the first-choice systemic treatment... For Tremfya, we think it's the first-choice biologic, particularly for patients that have potential for or have any psoriatic arthritis involvement…[These are] really distinct and unique positions for both."According to Taubert, over 18,000 prescriptions for Icotyde have been written to date for a total of 11,000 patients (see – Vital Signs: J&J maps megablockbuster trajectory for oral peptide). "That's an update from the 10,000 just shortly," she said. "There are 6000 unique prescribers, and if you take a look at those, over 50% are actually advanced practice providers."Pharma unit milestoneQuarterly sales for J&J's oncology portfolio grew 17.3% to $7.4 billion driven by products like Darzalex ($4.2 billion, +18.9%), Carvykti ($657 million. +49.4%) and Tecvayli ($260 million, +56.5%). Neuroscience therapies such as Spravato ($584 million, +40.8%) and Caplyta ($361 million, +70.9%) also saw significant growth."I think the second quarter was just an affirmation of the first quarter," Wolk said. "Our pharmaceutical unit continues to thrive, surpassing $16 billion in sales for the first time ever in the company's history."More to follow.

Drug ApprovalBiosimilar

100 Deals associated with Guselkumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10438	Guselkumab	L04AC16	DB11834

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Crohn's disease, active moderate	China	Janssen-Cilag International NV	20 Feb 2025
Crohn's disease, active severe	China	Janssen-Cilag International NV	20 Feb 2025
Ulcerative colitis, active moderate	United States	Janssen Biotech, Inc.	11 Sep 2024
Ulcerative colitis, active severe	United States	Janssen Biotech, Inc.	11 Sep 2024
Pustulosis of Palms and Soles	Japan	Janssen Pharmaceutical KK	21 Nov 2018
Colitis, Ulcerative	South Korea	Janssen Korea Ltd.	12 Apr 2018
Crohn Disease	South Korea	Janssen Korea Ltd.	12 Apr 2018
Keratoderma, Palmoplantar	South Korea	Janssen Korea Ltd.	12 Apr 2018
Erythrodermic psoriasis	Japan	Janssen Pharmaceutical KK	23 Mar 2018
Psoriasis	Japan	Janssen Pharmaceutical KK	23 Mar 2018
Pustular psoriasis	Japan	Janssen Pharmaceutical KK	23 Mar 2018
Arthritis, Psoriatic	European Union	Janssen-Cilag International NV	10 Nov 2017
Arthritis, Psoriatic	Iceland	Janssen-Cilag International NV	10 Nov 2017
Arthritis, Psoriatic	Liechtenstein	Janssen-Cilag International NV	10 Nov 2017
Arthritis, Psoriatic	Norway	Janssen-Cilag International NV	10 Nov 2017
Plaque psoriasis	United States	Janssen Biotech, Inc.	13 Jul 2017

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Juvenile Idiopathic Arthritis	NDA/BLA	United States	Johnson & Johnson	02 Dec 2024
Pediatric Crohn's Disease	Phase 3	United States	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	Japan	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	Australia	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	Austria	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	Belgium	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	Brazil	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	Canada	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	France	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	Israel	Janssen Research & Development LLC	13 Mar 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05272150 (VISIBLE trial \| VISIBLE study \| CNTO1959PSO3018 \| VISIBLE \| VISIBLE, CTgov)	Phase 3	Plaque psoriasis \| Psoriasis of scalp	211	Placebo+Guselkumab (Cohort A: Placebo Followed by Guselkumab 100 mg)	jnrqmustnr = ktszuisacv pnudfbrfrv (hlkstsgjie, oiauxfqjqe - iluonfcxof) View more	-	24 Jun 2026
				Guselkumab (Cohort A: Guselkumab 100 mg)	jnrqmustnr = wwsrcidxhe pnudfbrfrv (hlkstsgjie, hfsoubuvkn - vzxqrpcdxx) View more
NCT04645355 (TIG, CTgov)	Phase 4	Plaque psoriasis	17	Guselkumab (New-onset Guttate Psoriasis)	nkcvypncal(ngsrmwseqm) = smjkairgkr eygutvevfm (fvpuedifuo, 13.5) View more	-	23 Jun 2026
				Guselkumab (Chronic Plaque Psoriasis)	nkcvypncal(ngsrmwseqm) = tkmdnxutan eygutvevfm (fvpuedifuo, 23.4) View more
EULAR2026	Not Applicable	Arthritis, Psoriatic	160	Guselkumab	crzwkjazyv(iqqthrpalf) = fifwwhzmsp faxwwccyyw (frsjdjfazt ) View more	Positive	11 Jun 2026
EULAR2026	Not Applicable	Arthritis, Psoriatic	83	Guselkumab	hqifqhcivc(kbqzyznbtd) = faihvpojij slxzfloviv (aywentlffh ) View more	Positive	11 Jun 2026
APEX (EULAR2026)	Phase 3	Arthritis, Psoriatic	1,020	GUS 100 mg every 4 weeks	epttkfuiyb(tedivntpmy) = 59.2% [nominal p=0.042] and 61.1% [nominal p=0.006] vs 51.1% rrouzkngla (wymrydjtjb ) View more	Positive	11 Jun 2026
				GUS 100 mg at W0, W4, Q8W
NCT04882098 (APEX, EULAR2026)	Phase 3	Arthritis, Psoriatic	1,020	Guselkumab 100 mg Q4W	xojcxoasjj(zyjcwuvzwa) = mufgxtsqkw loyaghkivt (bpjbrlkmoj ) View more	Positive	11 Jun 2026
				Guselkumab 100 mg Q8W	xojcxoasjj(zyjcwuvzwa) = cssdricuqy loyaghkivt (bpjbrlkmoj ) View more
NCT04882098 (APEX, EULAR2026)	Phase 3	Arthritis, Psoriatic	344	Guselkumab Q4W	ddlvjpnpbx(csvkxjoxnq) = qzlxptacam rqvcvstszp (lmvxykfbze ) View more	Positive	11 Jun 2026
				Guselkumab Q8W	ddlvjpnpbx(csvkxjoxnq) = cuevvwtueq rqvcvstszp (lmvxykfbze ) View more
NCT04882098 (APEX, EULAR2026)	Phase 3	Arthritis, Psoriatic	1,020	Guselkumab 100 mg Q4W	ouyotkkyru(esnoyufmme) = jqyxzdfxqn haccrsmrqk (mlevjaansb )	Positive	11 Jun 2026
				Guselkumab 100 mg Q8W	ouyotkkyru(esnoyufmme) = spuvpsmepw haccrsmrqk (mlevjaansb )
EULAR2026	Not Applicable	Arthritis, Psoriatic	2,674	Guselkumab	wfhpodyrfi(vehlflajap) = tjhutjtiye ppqektgivv (sazbalaixw ) View more	Positive	11 Jun 2026
				TofacitinibApremilastUpadacitinib + TofacitinibApremilastUpadacitinib + TofacitinibApremilastUpadacitinib	wfhpodyrfi(vehlflajap) = ijiepigqqv ppqektgivv (sazbalaixw ) View more
NCT05049798 (PsABIOnd, EULAR2026)	Not Applicable	Arthritis, Psoriatic	1,141	Guselkumab	qqlrqczrfi(flaebwqrhy) = cuomxpiqsa mwwxgjpkin (vhypctxlyk ) View more	Positive	11 Jun 2026
				IL-17i	qqlrqczrfi(flaebwqrhy) = mkdztrasqs mwwxgjpkin (vhypctxlyk ) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data